Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 2/2011

01-04-2011 | Case Report

Mixed epithelial/mesenchymal metaplastic carcinoma (carcinosarcoma) of the breast in BRCA1 carrier

Authors: Evgeny N. Suspitsin, Anna P. Sokolenko, Dmitry A. Voskresenskiy, Alexandr O. Ivantsov, Kseniya V. Shelehova, Valery F. Klimashevskiy, Dmitry E. Matsko, Vladimir F. Semiglazov, Evgeny N. Imyanitov

Published in: Breast Cancer | Issue 2/2011

Login to get access

Abstract

This case report describes a 35-year-old woman who was diagnosed with mixed epithelial/mesenchymal metaplastic carcinoma (carcinosarcoma) of the breast. Genetic analysis of blood DNA revealed a common founder mutation, BRCA1 5382insC. Examination of microdissected tumor samples determined that both epithelial and mesenchymal components contained deletion of the wild-type BRCA1 allele. This report exemplifies that even very uncommon breast tumor types may develop through biallelic inactivation of BRCA1 gene, that has to be considered in the genetic testing settings.
Literature
1.
Hennessy BT, Gilcrease MZ, Babiera G, Yang W, Valero V, Hortobagyi GN. Carcinosarcoma of the breast. In: Raghavan D, Brecher ML, Johnson DH, Meropol NJ, Moots PL, Rose PG, Mayer IA, editors. Textbook of uncommon cancer. 3rd ed. New York: Wiley; 2006. p. 218–29.
2.
Teixeira MR, Qvist H, Bøhler PJ, Pandis N, Heim S. Cytogenetic analysis shows that carcinosarcomas of the breast are of monoclonal origin. Genes Chromosomes Cancer. 1998;22:145–51.PubMedCrossRef
3.
Sokolenko AP, Rozanov ME, Mitiushkina NV, Sherina NYu, Iyevleva AG, Chekmariova EV, et al. Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia. Fam Cancer. 2007;6:281–6.PubMedCrossRef
4.
Imyanitov EN, Suspitsin EN, Buslov KG, Kuligina ESh, Belogubova EV, Togo AV, Hanson KP. Isolation of nucleic acids from paraffin-embedded archival tissues and other difficult sources. In: Kieleczawa J, editor. DNA sequencing II: optimizing preparation and cleanup. Sudbury: Jones and Bartlett Publishers; 2006. p. 85–97.
5.
Lakhani SR. The pathology of familial breast cancer: morphological aspects. Breast Cancer Res. 1999;1:31–5.PubMedCrossRef
6.
van de Vijver MJ. The pathology of familial breast cancer: the pre-BRCA1/BRCA2 era: historical perspectives. Breast Cancer Res. 1999;1:27–30.PubMedCrossRef
7.
Honrado E, Benítez J, Palacios J. Histopathology of BRCA1- and BRCA2-associated breast cancer. Crit Rev Oncol Hematol. 2006;59:27–39.PubMedCrossRef
8.
Ashida A, Fukutomi T, Tsuda H, Akashi-Tanaka S, Ushijima T. Atypical medullary carcinoma of the breast with cartilaginous metaplasia in a patient with a BRCA1 germline mutation. Jpn J Clin Oncol. 2000;30:30–2.PubMedCrossRef
Metadata
Title
Mixed epithelial/mesenchymal metaplastic carcinoma (carcinosarcoma) of the breast in BRCA1 carrier
Authors
Evgeny N. Suspitsin
Anna P. Sokolenko
Dmitry A. Voskresenskiy
Alexandr O. Ivantsov
Kseniya V. Shelehova
Valery F. Klimashevskiy
Dmitry E. Matsko
Vladimir F. Semiglazov
Evgeny N. Imyanitov
Publication date
01-04-2011
Publisher
Springer Japan
Published in
Breast Cancer / Issue 2/2011
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-009-0105-0

Other articles of this Issue 2/2011

Breast Cancer 2/2011 Go to the issue

Case Report

A false positive for metastatic lymph nodes in the axillary region of a breast cancer patient following mastectomy

Special Feature

New trends in primary systemic therapy for breast cancer

Review Article

The microtubule as a breast cancer target

Original Article

Low incidence of methylation of the promoter region of the FANCF gene in Japanese primary breast cancer

Special Feature

Preoperative therapy: recent findings

Special Feature

Neoadjuvant endocrine therapy for postmenopausal patients with hormone receptor-positive early breast cancer: a new concept
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits